Other News To Note
Tuesday, March 20, 2012
MabCure Inc., of New York, said it entered an agreement with the City University of New York Center for Advanced Technology to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents. Terms were not disclosed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.